Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (20)

2024

  1. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis

    European Journal of Internal Medicine

  2. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

2023

  1. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

2022

  1. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

  2. Heart Transplantation in Systemic Sclerosis: A Therapeutic Option. Presentation of a Case and Literature Review

    Reumatologia Clinica, Vol. 18, Núm. 6, pp. 374-376

  3. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients

    Clinical and Experimental Rheumatology

  4. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    RMD Open, Vol. 8, Núm. 2

  5. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

2021

  1. Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients

    Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750

2020

  1. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 608-615

2018

  1. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

    Ophthalmology, Vol. 125, Núm. 9, pp. 1444-1451

2017

  1. Anti–Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients

    Arthritis and Rheumatology, Vol. 69, Núm. 3, pp. 668-675

  2. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3

2016

  1. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation

    Ocular Immunology and Inflammation, Vol. 24, Núm. 2, pp. 167-172

2015

  1. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 3, pp. 361-368

2014

  1. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients

    Rheumatology (Oxford, England), Vol. 53, Núm. 12, pp. 2223-2231

2009

  1. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 27, Núm. 6, pp. 920-925

2007

  1. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de la situación, 26 de enero de 2006

    Reumatologia Clinica, Vol. 3, Núm. 1, pp. 4-20

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1